Copay help by condition · Hormone, bone and metabolic · read 2026-11-08
Type 2 diabetes (T2DM): which charitable copay funds are open
All 3 funds we hold for Type 2 diabetes are closed or at capacity right now (read 2026-11-08).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Type 2 diabetes
- Closed or at capacityType 2 Diabetes
HealthWell Foundation ·
Award level: not statedInsurance supported: not stated
The page lists the fund as Closed. Source page
- Closed or at capacityType 2 diabetes (T2DM)
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $2,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
- Closed or at capacityType 2 diabetes (T2DM) health equity
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $2,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Type 2 diabetes
16 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 13 have a program (in our assistance finder or on the program's own page) and 6 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Farxiga Dapagliflozin Every route for this drug | As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Farxiga Savings (via AstraZeneca) Heart Medication Assistance (Multiple Programs) Diabetes Medication Assistance (Multiple Programs) AZ&Me Prescription Savings Program Not in its current list The program's page printed this drug in an earlier list and not in its current one. | $183.33 for a 30-day supply, effective 2027-01-01 |
| Trulicity Dulaglutide Every route for this drug | As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Trulicity Savings (via Lilly) Lilly Cares the page states new applications are once again being accepted and no longer require a medical exception request Diabetes Medication Assistance (Multiple Programs) | selected by CMS for 2028; price not yet published |
| Jardiance Empagliflozin Every route for this drug | ... as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Jardiance Savings (via Boehringer Ingelheim/Lilly) Heart Medication Assistance (Multiple Programs) Diabetes Medication Assistance (Multiple Programs) and 1 more | $202.33 for a 30-day supply, effective 2027-01-01 |
| Tradjenta Linagliptin Every route for this drug | TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Label on openFDA, read 2026-11-10 | Boehringer Ingelheim Cares Foundation Limited | $78.00 for a 30-day supply, effective 2027-01-01 |
| Janumet Metformin; Sitagliptin Every route for this drug | ... ion of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Merck Patient Assistance Program | $80.00 for a 30-day supply, effective 2027-01-01 |
| Ozempic Semaglutide Every route for this drug | ... as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Ozempic Savings (via NovoCare) Limited Novo Nordisk PAP (NovoCare) Limited 0.5 mg, 1 mg, or 2 mg Diabetes Medication Assistance (Multiple Programs) | $274.00 for a 30-day supply, effective 2027-01-01 |
| Januvia Sitagliptin Every route for this drug | JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Merck Patient Assistance Program Diabetes Medication Assistance (Multiple Programs) | $116.06 for a 30-day supply, effective 2027-01-01 |
| Invokana Canagliflozin Every route for this drug | ... as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Johnson & Johnson Patient Assistance Program | not in the CMS negotiated-price file |
| Glyxambi Empagliflozin/Linagliptin Every route for this drug | GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Label on openFDA, read 2026-11-10 | Boehringer Ingelheim Cares Foundation Limited | not in the CMS negotiated-price file |
| Synjardy XR, Synjardy Empagliflozin/Metformin Hcl Every route for this drug | ... nd metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Boehringer Ingelheim Cares Foundation Limited | not in the CMS negotiated-price file |
| Kerendia Finerenone Every route for this drug | FR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM). Label on openFDA, read 2026-11-10 | Bayer US Patient Assistance Foundation (program page) | not in the CMS negotiated-price file |
| Soliqua Insulin Glargine/Lixisenatide Every route for this drug | SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Sanofi Patient Connection | not in the CMS negotiated-price file |
| Mounjaro Tirzepatide Every route for this drug | MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | Mounjaro Savings (via Lilly) Diabetes Medication Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Victoza 3-Pak Liraglutide | ... to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial ... Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
| Metformin HCl Metformin Hcl | Metformin Hydrochloride Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
| Korlym Mifepristone | ... to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Related conditions
No broader or more specific condition page for this one.
Group: Hormone, bone and metabolic. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: type-2-diabetes.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Type 2 diabetes?
As read on 2026-11-08, none of the 3 funds we hold for Type 2 diabetes say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Type 2 diabetes?
HealthWell Foundation and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.